InMed Pharmaceuticals to Merge with Mentari Therapeutics, Securing $290M Funding & New Migraine Pipeline
INM sits 18% above its 52-week low of $0.575 on light trading volume (0.1× avg).
Summary
InMed Pharmaceuticals has announced a definitive all-stock merger agreement with privately-held Mentari Therapeutics, a biotechnology company focused on migraine prevention therapies. The combined entity will operate as Mentari Therapeutics and trade under a new Nasdaq ticker. This transformative deal includes a concurrent, oversubscribed US$290 million private placement for Mentari, which is expected to fund the combined company's operations through 2028. This merger provides a critical lifeline for InMed, which recently reported substantial going concern doubt, a short cash runway, and increased losses in its May 6th 10-Q filing. While likely highly dilutive for existing InMed shareholders, the significant capital infusion and new drug pipeline ensure the company's survival and provide a path forward. Traders will closely monitor the closing of the merger, the specifics of the all-stock transaction's impact on InMed's existing share structure, and the progress of Mentari's lead programs.
At the time of this announcement, INM was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.58 to $7.98. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: PR Newswire.